Plain-English answer
Cancer in China is not one disease market. It is a large, mixed burden involving lung, colorectal, thyroid, liver, stomach, breast, cervical, esophageal, and other cancers, each with different prevention, screening, diagnosis, treatment, reimbursement, and hospital-capacity needs.
2022 burden
IARC GLOBOCAN estimated 4.82 million new cancer cases and 2.57 million cancer deaths in China in 2022.
What the burden means
China's cancer burden combines "transition" cancers associated with aging, smoking, diet, obesity, and urban lifestyles with historically high-burden cancers linked to infection, environmental exposure, and late detection. IARC estimates for 2022 ranked lung, colorectal, thyroid, liver, and stomach cancers as the top five by new cases across both sexes. By deaths, lung, liver, and stomach cancers led. That difference matters: thyroid cancer produces many diagnoses but comparatively fewer deaths, while liver and stomach cancers remain highly lethal and closely tied to screening, infection control, and late-stage presentation.
The practical oncology question is where along the pathway a patient is lost or delayed. Prevention includes tobacco control, hepatitis B vaccination and treatment, HPV vaccination, food safety, occupational exposure reduction, and air pollution control. Detection includes organized screening for high-risk groups, endoscopy capacity, imaging, pathology, molecular testing, and primary-care referral. Treatment includes surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapies, palliative care, and reimbursement through the national drug list, local insurance, and hospital budgets.
Why it matters
China has built major oncology hospitals and a fast-moving drug approval and reimbursement environment, but the burden cannot be solved only through innovative medicines. Lung cancer alone was estimated at more than 1.06 million new cases and 733,291 deaths in 2022. Liver cancer deaths were estimated at 316,544 and stomach cancer deaths at 260,372. Those numbers point to prevention, early diagnosis, and regional oncology capacity as much as drug access.
The payer and provider issues are equally concrete. A PD-1 inhibitor, a radiotherapy system, a companion diagnostic, and a rural cancer screening program all sit in different decision systems. The right evidence may be survival data, cost-effectiveness, local budget impact, pathology workflow, specialist training, or referral design.
Interpretive caution
Do not treat "cancer in China" as a synonym for oncology drugs. The high-value questions differ by cancer type, stage at diagnosis, province, hospital tier, and payment route.
How to read the issue
Separate incidence from mortality
High incidence does not always mean high death burden; thyroid and liver cancer illustrate the difference.
Map the diagnostic chain
Screening, imaging, pathology, molecular testing, and staging determine whether treatment can be timely and appropriate.
Check affordability
Drug listing, hospital access, supplementary insurance, and out-of-pocket spending can shape actual uptake.
Strategic meaning
For strategy, cancer should be analyzed by pathway. Lung cancer raises questions about tobacco exposure, CT screening, pathology, EGFR/ALK/PD-L1 testing, thoracic surgery, radiotherapy, and systemic therapy. Liver cancer raises HBV, antiviral treatment, cirrhosis surveillance, interventional radiology, surgery, ablation, and transplant capacity. Colorectal cancer raises screening and endoscopy. Cervical cancer raises HPV vaccination and screening. The useful market or policy analysis begins with the cancer site, stage, and care setting, then asks who pays and which institution controls adoption.
Research anchors
| Source | What it adds | How to use it |
|---|---|---|
| IARC GLOBOCAN China 2022 fact sheet | Provides 2022 incidence, mortality, cancer ranking, and 5-year prevalence. | Use it for the headline cancer burden. |
| Cancer incidence and mortality in China, 2022 | National Cancer Center-based analysis of China's 2022 cancer patterns. | Use it for Chinese oncology epidemiology. |
| WHO tobacco in China | Explains the tobacco exposure behind lung cancer and CVD burden. | Use it for preventable-risk context. |